



**TEXAS**  
Health and Human  
Services

**Texas Department of State  
Health Services**

July 21, 2022

Dear Provider,

Federally funded distribution of bebtelovimab to states will end in mid-August. After federal distribution to states ends, it is anticipated that bebtelovimab will become available for provider purchase. Specifics for provider purchase are being developed by the manufacturer, Eli Lilly and Co, and DSHS will share details when they are available.

Although bebtelovimab is an alternative therapy recommended by the National Institutes of Health (NIH), it is not a top tier therapeutic for the treatment of COVID-19. [Paxlovid](#) and [Veklury](#) are the two top tier recommended therapeutics.

Per the [NIH Guidelines for Therapeutic Management of Nonhospitalized Adults](#) update on April 8, 2022, the preferred therapies are listed in order of preference:

- Paxlovid
- Veklury (remdesivir)

Alternative therapies for use when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:

- Bebtelovimab
- Lagevrio (molnupiravir)

Please use your best clinical judgement together with NIH guidelines, and consider prescribing the oral antiviral medication, Paxlovid, to all patients who are eligible. You may use the [HHS Therapeutics Locator](#) to find one of the thousands of Texas pharmacies that stock Paxlovid.

You may wish to purchase Veklury (remdesivir) for patients who are unable to take one of the oral antiviral medications. Hospitals can purchase Veklury through multiple distributors through the facility's normal procurement processes (Gilead Resource Call Center at 1-800-226-2056). Non-hospitals

can purchase from AmerisourceBergen ([Outpatient Product Information Guide including ordering](#)).

[VEKLURY](#) is indicated for the treatment of COVID-19 in adults and pediatric patients ( $\geq 28$  days old and weighing  $\geq 3$  kg) with positive results of SARS-CoV-2 viral testing, who are:

- Hospitalized, or
- Not hospitalized, have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

We appreciate all that you are doing to take care of Texans with COVID-19 and will provide more information about provider purchase of bebtelovimab when it is available.